X4 Pharmaceuticals
XFOR
89 hedge funds and large institutions have $73.2M invested in X4 Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 21 reducing their positions, and 21 closing their positions.
310% more call options, than puts
Call options by funds: $550K | Put options by funds: $134K
9% more capital invested
Capital invested by funds: $67.3M → $73.2M (+$5.92M)
10% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 21
0.04% less ownership
Funds ownership: 1.99% → 1.95% (-0.04%)
8% less funds holding
Funds holding: 97 → 89 (-8)
29% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 21
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$911K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$407K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$357K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$352K |
| 5 |
JP Morgan Chase
New York
|
+$204K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.86M |
| 2 |
PA
Perceptive Advisors
New York
|
-$2.37M |
| 3 |
SCM
Sio Capital Management
New York
|
-$872K |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$548K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$366K |
XFOR Hedge Fund Activity: Q4 2024 in Review
89 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q4 2024, worth a combined $73.2M — up 8.8% from $67.3M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of XFOR and 15 opened new positions — a net loss of 6 holders — while 21 trimmed existing stakes and 23 added.
The largest buyer was Susquehanna International Group, adding an estimated $911K. The largest seller was Adage Capital Partners, exiting entirely with an estimated $2.86M sold.
- 89 institutional investors held X4 Pharmaceuticals (XFOR) as of Q4 2024, down from 97 in Q3 2024.
- Funds reported $73.2M of X4 Pharmaceuticals stock for Q4 2024, up 8.8% quarter-over-quarter.
- 15 funds opened new X4 Pharmaceuticals positions in Q4 2024 and 21 closed out, a net change of -6 holders.
- The largest X4 Pharmaceuticals buyer in Q4 2024 was Susquehanna International Group, an estimated $911K added.
- The largest X4 Pharmaceuticals seller in Q4 2024 was Adage Capital Partners, an estimated $2.86M sold.
Based on aggregated 13F filings for Q4 2024.